Sandoz international

Index
Globenewswire

Sandoz Reaches Agreement with Amgen Resolving All Patent Litigation Related to its US Denosumab Biosimilars

Globenewswire

Sandoz Confirms European Commission Approval of Pyzchiva® (ustekinumab), Further Strengthening Immunology Offering

Globenewswire

Sandoz Opens New Antibiotic Production Facility in Austria, to Significantly Increase Capacity for Life-saving Medicines

Globenewswire

Sandoz Reports Fourth Quarter 2023 Sales and Full-year 2023 Results

Globenewswire

Sandoz Receives FDA Approval for First and Only Denosumab Biosimilars

Globenewswire

Sandoz Announces Nominations to the Board of Directors and Leadership Change

Globenewswire

Sandoz Acquires CIMERLI® Business from Coherus, Further Building Biosimilar and Ophthalmology Leadership in US Market

Globenewswire

Sandoz US Subsidiaries Resolve Generic Drug Antitrust Class Action Litigation with Direct Purchaser Class Plaintiffs

Globenewswire

Sandoz Announces Changes in the Board of Directors

Globenewswire

Sandoz Launches First and Only Biosimilar for Multiple Sclerosis, Tyruko® (Natalizumab), in Germany

Globenewswire

Sandoz Announces Agreement to Acquire CIMERLI® Business from Coherus, Strengthening Position in US Market

Globenewswire

Sandoz Launches Hyrimoz® (adalimumab) High-concentration Formulation in Europe, Aiming to Improve Patient Care

Globenewswire

Sandoz Inaugurates New Antibiotic Production Plant in Austria and New Biosimilar Development Center in Germany

Globenewswire

Sandoz Successfully Issues EUR 2.0 Billion Inaugural Eurobonds

Globenewswire

Sandoz Successfully Issues CHF 750 Million in Inaugural Bonds

Globenewswire

Sandoz Enters New Era as Standalone Global Leader and European Champion in Generic and Biosimilar Medicines